Osteoporosis
📧 Sign up to get email alerts when something new happens for Osteoporosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-02-12EMA Authorised: Adrovance (colecalciferol;alendronic acid (as sodium trihydrate)) — Organon N.V.
The European Medicines Agency authorised Adrovance, a fixed-dose combination of colecalciferol (vitamin D3) and alendronic acid (as sodium t…
-
EMA approval · 2026-02-06EMA Authorised: Bildyos (denosumab) — Sciencepharma Sp. z o.o
EMA authorised Bildyos, a denosumab medicine by Sciencepharma Sp. z o.o., for osteoporosis and postmenopausal osteoporosis related to bone r…
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for ibandronate sodium by Macleods Pharmaceuticals Limited.
-
FDA approval · 2026-02-03FDA Approved: ALENDRONATE SODIUM — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for alendronate sodium, updating the approved product under the ANDA.
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for ibandronate sodium submitted by Dr. Reddy's Laboratories Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-02-03FDA Approved: BINOSTO — Supplemental Application (Radius Health, Inc.)
FDA approved a supplemental application for BINOSTO (alendronate sodium) submitted by Radius Health, Inc. The approval concerns an update to…
-
FDA approval · 2026-02-03FDA Approved: FOSAMAX PLUS D — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for Fosamax Plus D (alendronate sodium and cholecalciferol) submitted by Organon LLC.
-
FDA approval · 2026-02-03FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s supplemental application for ALENDRONATE SODIUM, indicating an approved change under the ANDA …
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp)
FDA approved Apotex Corp's supplemental application for ibandronate sodium, granting approval of a generic version. Ibandronate is used to t…
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for ibandronate sodium filed by Apotex Corp., under ANDA 204222.
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Ibandronate Sodium submitted by Mylan Institutional LLC.
-
FDA approval · 2026-02-03FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ibandronate sodium submitted by Aurobindo Pharma Limited, confirming regulatory approval for thi…
-
EMA approval · 2026-01-30EMA Authorised: Osvyrti (denosumab) — Accord Healthcare S.L.U.
The EMA authorised Osvyrti, a denosumab product from Accord Healthcare S.L.U., for bone resorption disorders including osteoporosis and post…
-
EMA approval · 2026-01-28EMA Authorised: Forsteo (teriparatide) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Forsteo (teriparatide) for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-27EMA Authorised: Optruma (raloxifene hydrochloride) — Eli Lilly Nederland B.V.
The EMA authorised Optruma (raloxifene hydrochloride) from Eli Lilly Nederland B.V. for osteoporosis in postmenopausal women.
-
EMA approval · 2026-01-20EMA Authorised: Ponlimsi (denosumab) — Teva GmbH
The EMA authorised Ponlimsi (denosumab) by Teva GmbH on 19 January 2026 for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-14EMA Authorised: Stoboclo (denosumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Stoboclo (denosumab) by Celltrion Healthcare Hungary Kft. for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-06EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.
EMA authorised Obodence (denosumab) by Samsung Bioepis NL B.V. for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2026-01-05EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.
EMA authorised Junod, a denosumab product from Gedeon Richter, for osteoporosis and postmenopausal osteoporosis.
-
FDA approval · 2025-12-12FDA Approved: TERIPARATIDE — Original Application (Amphastar Pharmaceuticals, Inc.)
FDA approved Amphastar Pharmaceuticals' original application for a generic teriparatide product.
-
EMA approval · 2025-12-10EMA Authorised: Livogiva (teriparatide) — Theramex Ireland Limited
The European Medicines Agency has authorised Livogiva, a teriparatide product by Theramex Ireland Limited, for the treatment of osteoporosis…
-
EMA approval · 2025-12-02EMA Authorised: Izamby (denosumab) — Mabxience Research SL
The EMA authorised Izamby (denosumab) for osteoporosis-related bone resorption disorders, including postmenopausal osteoporosis, with Mabxie…
-
EMA approval · 2025-11-27EMA Authorised: Rolcya (denosumab) — Sandoz GmbH
The EMA authorised Rolcya, a denosumab product by Sandoz GmbH, for osteoporosis including postmenopausal osteoporosis.
-
EMA approval · 2025-11-27EMA Authorised: Jubbonti (denosumab) — Sandoz GmbH
EMA authorised Jubbonti, a denosumab product from Sandoz GmbH, for osteoporosis and postmenopausal osteoporosis, reflecting its use in reduc…
-
FDA approval · 2025-10-29FDA Approved: WYOST — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for WYOST (denosumab) submitted by Sandoz Inc, expanding the product's indications.